AcelRx Pharmaceuticals Transitions to Talphera, Introduces New Nasdaq Symbol by Investing.com

AcelRx Pharmaceuticals rebrands as Talphera, expanding its therapeutic focus beyond acute pain management. Talphera aims to lead with innovative therapies and will begin trading on Nasdaq with the ticker symbol "TLPH." Niyad, Talphera's lead product candidate, receives FDA Breakthrough Designation as an anticoagulant for extracorporeal circuits in renal replacement therapy. Talphera's NEPHRO CRRT Study, evaluating the effectiveness of Niyad, gets IRB approval, offering potential alternatives to patients unable to tolerate heparin or at risk for bleeding. The rebranding reflects Talphera's commitment to innovation in the pharmaceutical industry.